ZMapp is a combination of three chimeric antibodies effective in Ebola-infected monkeys.[11] The limited supply of the drug was used to treat a small number of individuals infected with the Ebola virus early on in the 2014-5 West Africa outbreak; although some individuals recovered, the outcome is not considered statistically significant.[12][13] A Phase 1/2 trial started in Liberia and the United States on 27 February 2015.[14][15] Favipiravir (Avigan) is a broad-spectrum antiviral drug, which appears to be useful in a mouse model of Ebola disease.[16][17] A Phase 2 clinical trial started in Guinea during December 2014,[18][19] with early reports indicating that it has some benefit.[20]